ATE269412T1 - Rekombinanter adeno-assoziierter viraler vektor, der alpha-1 antitrypsin kodiert, zur gentherapie - Google Patents

Rekombinanter adeno-assoziierter viraler vektor, der alpha-1 antitrypsin kodiert, zur gentherapie

Info

Publication number
ATE269412T1
ATE269412T1 AT99918810T AT99918810T ATE269412T1 AT E269412 T1 ATE269412 T1 AT E269412T1 AT 99918810 T AT99918810 T AT 99918810T AT 99918810 T AT99918810 T AT 99918810T AT E269412 T1 ATE269412 T1 AT E269412T1
Authority
AT
Austria
Prior art keywords
gene therapy
methods
antitrypsin
viral vector
vector encoding
Prior art date
Application number
AT99918810T
Other languages
English (en)
Inventor
Terence R Flotte
Sihong Song
Barry J Byrne
Michael Morgan
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Priority claimed from PCT/US1999/008921 external-priority patent/WO1999055564A2/en
Application granted granted Critical
Publication of ATE269412T1 publication Critical patent/ATE269412T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99918810T 1998-04-24 1999-04-23 Rekombinanter adeno-assoziierter viraler vektor, der alpha-1 antitrypsin kodiert, zur gentherapie ATE269412T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8302598P 1998-04-24 1998-04-24
PCT/US1999/008921 WO1999055564A2 (en) 1998-04-24 1999-04-23 Materials and methods for gene therapy

Publications (1)

Publication Number Publication Date
ATE269412T1 true ATE269412T1 (de) 2004-07-15

Family

ID=22175690

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99918810T ATE269412T1 (de) 1998-04-24 1999-04-23 Rekombinanter adeno-assoziierter viraler vektor, der alpha-1 antitrypsin kodiert, zur gentherapie

Country Status (11)

Country Link
US (4) US6461606B1 (de)
EP (1) EP1071806B1 (de)
AT (1) ATE269412T1 (de)
AU (1) AU3663699A (de)
CA (1) CA2326327C (de)
DE (1) DE69918090T2 (de)
DK (1) DK1071806T3 (de)
ES (1) ES2219011T3 (de)
HK (1) HK1035205A1 (de)
NZ (1) NZ507308A (de)
PT (1) PT1071806E (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759237B1 (en) * 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
AU5882801A (en) 2000-05-26 2001-12-03 Sumitomo Pharmaceuticals Company, Limited Novel recombinant adenovirus vector with relieved side effects
EP1390490B1 (de) * 2001-05-24 2009-04-15 Genzyme Corporation Muskelspezifische expressionsvektoren
US7312202B2 (en) * 2003-02-18 2007-12-25 Board Of Regents, The University Of Texas System Rationally designed and chemically synthesized promoter for genetic vaccine and gene therapy
ES2247942B1 (es) * 2004-08-27 2006-10-01 Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria (Inia) Construccion genica, vector y vacuna adn para la vacunacion de animales acuaticos.
US7479550B2 (en) * 2006-06-02 2009-01-20 The Board Of Regents Of The University Of Texas System Amyloid β gene vaccines
JP5635912B2 (ja) * 2008-01-15 2014-12-03 アッヴィ・インコーポレイテッド 改善された哺乳動物発現ベクター及びその使用
US9375491B2 (en) 2011-10-28 2016-06-28 University Of Florida Research Foundation, Inc. Chimeric promoter for cone photoreceptor targeted gene therapy
EP2802338B1 (de) 2012-01-09 2018-03-07 Serpin Pharma, LLC Peptide und verwendungsverfahren dafür
US11446366B2 (en) 2015-02-05 2022-09-20 Canem Holdings, Llc Compositions and methods for treating granulomatosis with polyangiitis
PT3265571T (pt) 2015-03-03 2022-06-29 Fond Telethon Sistema de vetor múltiplo e uso do mesmo
CN113429455A (zh) 2015-08-28 2021-09-24 赛品制药有限责任公司 用于疾病治疗的方法
US20200230207A1 (en) 2015-09-28 2020-07-23 Fondazione Telethon Treatment of bone growth disorders
PT3723790T (pt) * 2017-12-12 2024-05-10 Kamada Ltd Métodos de indução de tolerância imunitária e de redução da resposta de anticorpos antifármacos
AU2020223367A1 (en) * 2019-02-15 2021-10-07 Allen Institute Artificial expression constructs for selectively modulating gene expression in selected neuronal cell populations
KR20220164743A (ko) * 2020-04-06 2022-12-13 호몰로지 메디슨, 인크. Ids 유전자 전달을 위한 아데노-연관 바이러스 조성물 및 이의 사용 방법
WO2023213817A1 (en) 2022-05-02 2023-11-09 Fondazione Telethon Ets Gene therapy for gyrate atrophy of the choroid and retina
WO2024036250A2 (en) * 2022-08-10 2024-02-15 Homology Medicines, Inc. Adeno-associated virus compositions for arsa gene transfer and methods of use thereof
WO2024184376A1 (en) 2023-03-09 2024-09-12 International Centre For Genetic Engineering And Biotechnology - Icgeb Human alpha galactosidase a coding sequence for the treatment of fabry disease
CN117223676B (zh) * 2023-09-25 2024-08-20 武汉大学 面中部发育畸形动物选育方法、辅助选育试剂和预防药物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6261834B1 (en) * 1991-11-08 2001-07-17 Research Corporation Technologies, Inc. Vector for gene therapy
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5439824A (en) * 1993-05-06 1995-08-08 The United States Of America Increased expression of α-1-antitrypsin in expression vectors through the inclusion of intron II
WO1995013365A1 (en) 1993-11-09 1995-05-18 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US5693531A (en) * 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6204059B1 (en) * 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5652224A (en) * 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US6723707B1 (en) * 1997-08-25 2004-04-20 The Trustees Of The University Of Pennsylvania Use of insulin-like growth factor-I in muscle

Also Published As

Publication number Publication date
WO1999055564A8 (en) 1999-12-02
ES2219011T3 (es) 2004-11-16
EP1071806A2 (de) 2001-01-31
US6461606B1 (en) 2002-10-08
PT1071806E (pt) 2004-09-30
HK1035205A1 (en) 2001-11-16
DK1071806T3 (da) 2004-07-19
US20090186002A1 (en) 2009-07-23
CA2326327C (en) 2009-06-16
NZ507308A (en) 2003-01-31
CA2326327A1 (en) 1999-11-04
AU3663699A (en) 1999-11-16
US20030082162A1 (en) 2003-05-01
EP1071806B1 (de) 2004-06-16
WO1999055564A1 (en) 1999-11-04
DE69918090T2 (de) 2005-06-16
DE69918090D1 (de) 2004-07-22
US20030095949A1 (en) 2003-05-22
WO1999055564A9 (en) 2000-04-06

Similar Documents

Publication Publication Date Title
DE69918090D1 (de) Rekombinanter adeno-assoziierter viraler vektor, der alpha-1 antitrypsin kodiert, zur gentherapie
DE69834936D1 (de) Vektor zur gewebespezifischen replikation und expression
DE69635173D1 (de) Rekombinante MVA Viren und deren Verwendung
DE69528054D1 (de) In prostata aktiver gewebespezifischer enhancer
DK1019073T3 (da) Apoliprotein A-I agonister og deres anvendelse til at behandle dyslipidæmiske lidelser
ATE314482T1 (de) Rekombinante adenoviren-vektor und verfahren zur verwendung
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
WO2002044320A3 (en) Human elongase genes and uses thereof
NZ257484A (en) Nucleotides active against tnf-alpha, treatment of viral diseases
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
TR200100348T2 (tr) Gen tedavisi teknikleri
CO5280032A1 (es) COMPOSICIONES RELACIONADAS CON ESTEAROIL-CoA DESATURASA HUMANA Y METODOS PARA TRATAR DESORDENES DE LA PIEL
ATE374783T1 (de) ßALPHA1-UNTEREINHEIT DES NATRIUMKANALS, POLYPEPTIDE DAVON UND DEREN VERWENDUNG ZUR BEHANDLUNG VON GENERALISIERTER EPILEPSIE MIT FIEBERANFÄLLEN PLUS ß
ATE338814T1 (de) Verfahren zur kultivierung von zellen und zur vermehrung von viren
DE60315628D1 (de) Modifizierte cea nucleinsäure und expressionsvektoren
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
DK0684842T3 (da) Præparat til behandling af tumorer og immunisering af organismer over for tumorer
DK0722496T3 (da) Farmaceutiske præparater og anvendelse af disse, især til behandling af neurodegenerative sygdomme
ATE364625T1 (de) Proteine aus yaba monkey tumor virus mit modulatorischer aktivität
NO964894D0 (no) Rekombinante viruser, deres fremstilling samt anvendelse av genterapi
DE59801718D1 (de) Verwendung von escherichia coli stamm dsm 6601 zur behandlung von diarrhoeen auf dem veterinärsektor
DE69910608D1 (de) Neue therapeutische verwendung von 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1071806

Country of ref document: EP